Aimovig® offers the flexibility of 2 different dosing options1
- The recommended dosage of Aimovig® is 70 mg once monthly; some patients may benefit from 140 mg once monthly1
- No loading dose1
- No dose adjustment required for special populations1
- Hidden 27-gauge needle3
- Doses may be administered subcutaneously in the upper arm, thigh, or abdomen1,*
In a usability study of the SureClick® autoinjector among adult migraine patients (N = 204)4,†:
found the autoinjectoreasy to use
would recommend the autoinjector to other patients
The AHS recommends assessing the benefits of anti-CGRP mAb therapy after 3 months of treatment for those administered monthly.5
*Administration in the upper arm requires a caregiver to inject.1
†204 autoinjector-naïve adult migraine patients were evaluated in a usability study of the Aimovig SureClick® single-dose autoinjector by performing a simulated injection. Percentage was derived from a combination of patients who stated completely agree or somewhat agree on a 5-point Likert scale.4
Show your patients this overview video on injecting Aimovig®
It is important that you thoroughly review the Instructions for Use. The 70 mg and 140 mg instructions cover everything you need to know about how to use the Aimovig SureClick® autoinjector. The information on this website does not replace the Instructions for Use.
AHS = American Headache Society; CGRP = calcitonin gene-related peptide; mAb = monoclonal antibody.
